Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8315415 | 0.80 | ACP3 (0.47) | TAAR1TSHRALDH1A1 | |
| SCHEMBL8317456 | 0.80 | ACP3 (0.51) | HTR2AHRH1TSHRALDH1A1MTOR | |
| SCHEMBL9452584 | 0.79 | HTR2A (0.43) | HTR2ATAAR1HRH1DPP4TSHR | |
| SCHEMBL1318953 | 0.77 | LMNA (0.61) | TSHRRAB9A | |
| SCHEMBL6891173 | 0.77 | LMNA (0.61) | TSHRRAB9A | |
| SCHEMBL24164093 | 0.77 | LMNA (0.61) | TSHRRAB9A | |
| SCHEMBL3578847 | 0.77 | LMNA (0.61) | TSHRRAB9A | |
| SCHEMBL331173 | 0.77 | TRPA1 (0.42) | HTR2ATAAR1HRH1DPP4TSHR | |
| SCHEMBL2172475 | 0.77 | HRH1 (0.56) | HTR2ATAAR1HRH1TDP1ALDH1A1 | |
| SCHEMBL193835 | 0.75 | HTR2A (0.52) | HTR2ATAAR1HRH1TDP1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000188-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2309860-B1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | DARTMOUTH COLLEGE (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130274480-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8314137-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTESS OF DARTMOUTH COLLEGE (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110196007-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-11 | — | — | US | disclosed |
| EP-2352768-A2 | CURABLE COMPOSITION FOR IMPRINTS, PATTERNING METHOD AND PATTERN | FUJIFILM Corporation (JP) | 2011-08-10 | — | — | EP | disclosed |
| EP-2309860-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | Trustees of Dartmouth College (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010064726-A2 | CURABLE COMPOSITION FOR IMPRINTS, PATTERNING METHOD AND PATTERN | FUJIFILM CORPORATION (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010011782-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2010-01-28 | — | — | WO | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997048705-A1 | POTASSIUM CHANNEL BLOCKERS | UNIVERSITY COLLEGE LONDON (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196007-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | HSD17B7, HSD17B12, CYP11B2 | HTR2A 1848/4885TAAR1 1893/4885HRH1 4107/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | HTR2A 288/4885TAAR1 209/4885HRH1 2734/4885 |
| US-20130274480-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | HSD17B7, HSD17B12, CYP11B2 | HTR2A 1848/4885TAAR1 1893/4885HRH1 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.